

Date: 07/01/2022

Important Information For Pharmacists

Product	PA Number	Unavailability Date	Resupply Date
Denzapine 50 mg/ml Oral Suspension	PA0126/235/005	January 2022	Start of February 2022

Dear Pharmacist,

Clonmel Healthcare Ltd would like to advise you of a temporary supply interruption of Denzapine 50 mg/ml Oral Suspension due to a manufacturing delay.

In order to address a short-term stock shortage in respect of Denzapine 50mg/ml Oral Suspension, Clonmel Healthcare Ltd. is supplying Denzapine 50mg/ml Oral Suspension from the United Kingdom market (BN: B5610, EXP: 03/2022). This will be supplied as an Exempt medicinal product (EMP) on the Irish market upon request from a hospital doctor.

Denzapine 50mg/ml Oral Suspension product composition is identical for both the Irish and UK markets. **As the product is an EMP please do not scan the 2D barcode.**

Denzapine 50mg/ml Oral Suspension from the UK market differs in the following respects from the Irish product:

- Packaging design
- The marketing authorisation number, name and address of marketing authorisation holder
- Details on the patient information leaflet on reporting adverse drug reactions

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: HPRa Pharmacovigilance. Website: www.hpra.ie



Niall Hally
Denzapine Monitoring Service